Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK

European Journal of Health Economics

Volumn 4, Issue 3, 2003, Pages 216-221

  Aristides, M ^a   Lees, M ^a   Botwood, N ^b   McKendrick, J ^b   Stephenson, D A ^b   Maniadakis, N ^b  

^a M TAG   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

5 Fluorouracil; Cost effectiveness; Gemcitabine; Pancreatic cancer

Indexed keywords

FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

EID: 0141961839     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-003-0173-6     Document Type: Article

References (21)

1. Office of National Statistics (2000)www.statistics. gov.uk/statbase/
2. Manu M, Buchels J (1999) Pancreatic cancer. Oncol Update 4:443-448
3. Bramhall SR, Allum WH, Jones AG (1995) Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1:111-115
4. Haycox A, Lombard M, Neoptolemos J, et al (1998) Current practice and future perspectives in detection and diagnosis of pancreatic cancer. Aliment Pharmacol Ther 12:937-948
5. Gudjonsson B (1987) Cancer of the pancreas: 50 years of surgery. Cancer 60:2284-2303
6. Rothman H, Cantrell JE, Lokich J, et al (1991) Continuous infusion of 5-FU plus weekly cisplatin for pancreatic carcinoma. A mid-Atlantic oncology program study. Cancer 68:264-248
7. Ross PJ, Webb A, Cunningham D, Prendiville J, Norman AR, Oates J (1997) Infusional 5-FU in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience. Ann Oncol 8:111-115
8. Burris HA, Moore MJ, Anderson J, et al (1997) Improvement in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreatic cancer: a randomised trial. J Clin Oncol 15:2403-2413
9. Anonymous (2000) British national formulary (BNF 40). British Medical Association, Royal Pharmaceutical Society of Great Britain
10. Netten A, Dennett J, Knight J (1999) Unit costs of health and social care. Personal Social Services Research Unit, University of Kent: Canterbury
11. National Casemix Office (1999) HRG explorer. NHS Information Authority: Winchester
12. UK Department of Health (1999) National schedule of reference costs 1999. NHS Executive, UK Department of Health: Leeds
13. Klein JP, Moeschberger ML (1997) Survival analysis: methods for censored and truncated data. Springer: Berlin Heidelberg NewYork pp 109-114
14. Glimelius B (1998) Chemotherapy in the treatment of cancer of the pancreas. J Hepatobiliary Pancreat Surg 5:235-241
15. Rothenburg M, Moore M, Cripps M, et al (1996) A phase II trial of gemcitabine patients with 5-FU refractory pancreas cancer. Ann Oncol 7:347-353
16. Storniolo AM, Enas N, Brown C, et al (1999) An investigational new drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261-1268
17. Heinemann V (2001) Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 60:8-18
18. Oettle H, Arnold D, Hempel C, Riess H (2000) The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 11:771-786
19. National Institute for Clinical Excellence (2003) Completed technology appraisals.http://www.nice.org.uk/ catlist.asp?c=153 (accessed February 2003)
20. Ragnarson-Tennvall G, Wilking N (1999) Treatment of locally advanced pancreatic carcinoma in Sweden: a health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care. Pharmacoeconomics 15:377-384
21. National Institute for Clinical Excellence (2001) Guidance on the use of gemcitabine for the treatment of pancreatic cancer. http://www.nice.org.uk.pdf/gemcitabineguidance.pdf (accessed May 2001)